Montelukast Teva (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as a medication for buccal, cutaneous, dental and nasal use. It is employed to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation for global distribution.

Montelukast Teva is a leukotriene receptor antagonist used to treat conditions mediated by cysteinyl leukotrienes.

Asthma: improves control of chronic airway inflammation and reduces frequency of exacerbations. Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergic triggers. Exercise‑induced bronchoconstriction: prevents narrowing of airways that occurs during or after physical activity.

Montelukast may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache - Abdominal pain - Nausea - Dizziness

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Neuropsychiatric events such as depression or suicidal thoughts - Hepatic enzyme elevation or liver injury

When prescribing Montelukast, clinicians should consider several safety measures.

Assess asthma control: ensure baseline therapy is optimized before adding Montelukast. Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. Avoid in patients with known hypersensitivity to Montelukast or any tablet components. Adjust use in hepatic impairment: consider liver function monitoring in moderate to severe disease. Store at room temperature: keep in the original container, protect from moisture and heat.

Montelukast can interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Montelukast plasma concentrations. - Phenobarbital and other potent enzyme inducers: may markedly reduce Montelukast effectiveness.

Moderate Interactions (Monitor Closely): - Rifampin: may lower drug levels, requiring clinical monitoring. - Fluconazole: moderate CYP3A4 inhibition may modestly raise exposure. - Carbamazepine: enzyme induction may decrease therapeutic effect.